Glecaprevir (INN,[1]) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals.[2] It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir. Together they demonstrated potent antiviral activity against major HCV genotypes and high barriers to resistance in vitro.[3]
On 19 December 2016, AbbVie submitted a new drug application to the U.S. Food and Drug Administration for the glecaprevir/pibrentasvir (trade name Mavyret) regimen for the treatment of all major genotypes (1–6) of chronic hepatitis C. On 3 August 2017 the FDA approved the combination for hepatitis C treatment.[4] In Europe, it was approved on 17 August 2017 for the same indication, under the trade name Maviret.[5]
^"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 76" (PDF). World Health Organization. p. 503. Retrieved 25 February 2017.
^Notman, Nina (August 14, 2023). . Chemical & Engineering News. Vol. 101, no. 26. Archived from the original on 2024-03-16. Retrieved 2024-04-04.
^Lawitz EJ, O'Riordan WD, Asatryan A, Freilich BL, Box TD, Overcash JS, et al. (December 2015). "Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection". Antimicrobial Agents and Chemotherapy. 60 (3): 1546–55. doi:10.1128/AAC.02264-15. PMC4775945. PMID 26711747.
^"AbbVie Submits New Drug Application to U.S. FDA for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C." AbbVie Inc. North Chicago, Illinois, U.S.A. December 19, 2016. Retrieved 25 February 2017.
glecaprevir, hepatitis, virus, nonstructural, protein, protease, inhibitor, that, identified, jointly, abbvie, enanta, pharmaceuticals, being, developed, treatment, chronic, hepatitis, infection, formulation, with, ns5a, inhibitor, pibrentasvir, together, they. Glecaprevir INN 1 is a hepatitis C virus HCV nonstructural NS protein 3 4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals 2 It is being developed as a treatment of chronic hepatitis C infection in co formulation with an HCV NS5A inhibitor pibrentasvir Together they demonstrated potent antiviral activity against major HCV genotypes and high barriers to resistance in vitro 3 GlecaprevirClinical dataTrade namesMavyret combination with pibrentasvir Other namesABT 493Routes ofadministrationBy mouthATC codeNonePharmacokinetic dataProtein binding97 5 MetabolismCYP3AElimination half life6 hoursExcretionFaeces 92 1 urine 0 7 IdentifiersIUPAC name 3aR 7S 10S 12R 21E 24aR 7 tert Butyl N 1R 2R 2 difluoromethyl 1 1 methylcyclopropane 1 sulfonyl carbamoyl cyclopropyl 20 20 difluoro 5 8 dioxo 2 3 3a 5 6 7 8 11 12 20 23 24a dodecahydro 1H 10H 9 12 methanocyclopenta 18 19 1 10 17 3 6 trioxadiazacyclonon adecino 11 12 b quinoxaline 10 carboxamideCAS Number1365970 03 1 YPubChem CID66828839DrugBankDB13879ChemSpider35013015UNIIK6BUU8J72PKEGGD10814Chemical and physical dataFormulaC 38H 46F 4N 6O 9SMolar mass838 87 g mol 13D model JSmol Interactive imageSMILES CC C C C H 1NC O O C H 2CCC C H 2OC C C C F F c2nc3ccccc3nc2O C H 2C C H C O N C 3 C O NS O O C4 C CC4 C C H 3C F F N C2 C1 OInChI InChI 1S C38H46F4N6O9S c1 35 2 3 28 32 50 48 19 20 17 24 48 30 49 46 37 18 21 37 29 39 40 33 51 47 58 53 54 36 4 14 15 36 56 31 27 43 22 9 5 6 10 23 22 44 31 38 41 42 13 8 16 55 25 11 7 12 26 25 57 34 52 45 28 h5 6 8 10 13 20 21 24 26 28 29H 7 11 12 14 19H2 1 4H3 H 45 52 H 46 49 H 47 51 b13 8 t20 21 24 25 26 28 37 m1 s1Key MLSQGNCUYAMAHD ITNVBOSISA NOn 19 December 2016 AbbVie submitted a new drug application to the U S Food and Drug Administration for the glecaprevir pibrentasvir trade name Mavyret regimen for the treatment of all major genotypes 1 6 of chronic hepatitis C On 3 August 2017 the FDA approved the combination for hepatitis C treatment 4 In Europe it was approved on 17 August 2017 for the same indication under the trade name Maviret 5 See also editProtease inhibitor pharmacology References edit International Nonproprietary Names for Pharmaceutical Substances INN Recommended International Nonproprietary Names List 76 PDF World Health Organization p 503 Retrieved 25 February 2017 Notman Nina August 14 2023 ACS names its 2023 Heroes of Chemistry Chemical amp Engineering News Vol 101 no 26 Archived from the original on 2024 03 16 Retrieved 2024 04 04 Lawitz EJ O Riordan WD Asatryan A Freilich BL Box TD Overcash JS et al December 2015 Potent Antiviral Activities of the Direct Acting Antivirals ABT 493 and ABT 530 with Three Day Monotherapy for Hepatitis C Virus Genotype 1 Infection Antimicrobial Agents and Chemotherapy 60 3 1546 55 doi 10 1128 AAC 02264 15 PMC 4775945 PMID 26711747 AbbVie Submits New Drug Application to U S FDA for its Investigational Regimen of Glecaprevir Pibrentasvir G P for the Treatment of All Major Genotypes of Chronic Hepatitis C AbbVie Inc North Chicago Illinois U S A December 19 2016 Retrieved 25 February 2017 Maviret EPAR Summary for the public PDF European Medicines Agency 2017 08 17 nbsp This antiinfective drug article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Glecaprevir amp oldid 1217225557, wikipedia, wiki, book, books, library,
